Lexeo Therapeutics, Inc. Common Stock (LXEO) — Financial statements
Income statement, balance sheet, and cash flow for Lexeo Therapeutics, Inc. Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00↓100.0% | 0.65↓60.5% | 2 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00↓100.0% | 0.65↓60.5% | 2 | |
| Operating Expenses | ||||||
| R&D Expenses | 64↓13.9% | 74↑39.5% | 53↑8.1% | 49↑9.0% | 45 | |
| General & Administrative Expenses | 45↑43.5% | 32↑105.9% | 15↑28.2% | 12↑67.3% | 7 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 45↑43.5% | 32↑105.9% | 15↑28.2% | 12↑67.3% | 7 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 109↑3.3% | 106↑54.4% | 69↑12.0% | 61↑17.0% | 52 | |
| Total Costs & Expenses | 109↑3.3% | 106↑54.4% | 69↑12.0% | 61↑17.0% | 52 | |
| Operating Results | ||||||
| Operating Income | -109↓3.3% | -106↓54.4% | -69↓13.2% | -61↓19.5% | -51 | |
| Depreciation & Amortization | 2↑3.8% | 2↑8.6% | 2↑61.0% | 1↑8707.7% | 0.01 | |
| EBITDA | -98↓1.5% | -96↓49.5% | -64↓10.9% | -58↓14.7% | -51 | |
| EBIT | -100↓1.6% | -98↓48.4% | -66↓11.8% | -59↓16.9% | -51 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↓20.4% | 7↑179.6% | 3↑115.7% | 1↑8126.7% | 0.02 | |
| Interest Income | 6↓18.9% | 8↑163.6% | 3↑116.4% | 1↑8733.3% | 0.02 | |
| Interest Expense | 0.21↑80.7% | 0.11↓44.4% | 0.21↑125.3% | 0.09 | 0.00 | |
| Non-Operating Income | -10↓25.5% | -8↓225.7% | -2↓75.7% | -1↓8720.0% | -0.02 | |
| Other Income / Expenses | 9↑25.1% | 7↑250.8% | 2↑72.0% | 1↑8113.3% | 0.02 | |
| Income Before Tax | -100↓1.7% | -98↓48.1% | -66↓12.0% | -59↓17.1% | -51 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -100↓1.7% | -98↓48.1% | -66↓12.0% | -59↓17.1% | -51 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -100↓1.7% | -98↓48.1% | -66↓12.0% | -59↓17.1% | -51 | |
| Bottom-Line Net Income | -100↓1.7% | -98↓48.1% | -66↓12.0% | -59↓17.1% | -51 | |
| EPS (Basic) | -1.86↑39.8% | -3.09↓24.1% | -2.49↓5.5% | -2.36↓17.4% | -2.01 | |
| EPS (Diluted) | -1.86↑39.8% | -3.09↓24.1% | -2.49↓3.8% | -2.40↓19.4% | -2.01 | |
| Weighted Average Shares | 54↑68.8% | 32↑19.3% | 27↑5.9% | 25↑0.0% | 25 | |
| Weighted Average Diluted Shares | 54↑68.8% | 32↑19.3% | 27↑5.9% | 25↑0.0% | 25 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.